CPC A61K 31/4709 (2013.01) [A61K 45/06 (2013.01); A61N 5/10 (2013.01); G01N 33/573 (2013.01); A61K 31/337 (2013.01); A61K 31/4184 (2013.01); A61K 31/444 (2013.01); A61K 31/47 (2013.01); G01N 2333/912 (2013.01)] | 21 Claims |
1. A method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or expression in a subject with a proliferative disease which comprises administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I:
or a pharmaceutically acceptable salt or solvate thereof, wherein the proliferative disease is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, idiopathic hypereosinophilic syndrome (HES), bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and hematologic malignancy.
|